
Journal Basic Info
- Impact Factor: 1.809**
- H-Index: 6
- ISSN: 2474-1655
- DOI: 10.25107/2474-1655
Major Scope
- Depression
- Cardiovascular Medicine
- Endoscopy
- Emergency Medicine and Critical Care
- Dermatology and Cosmetology
- Trauma
- Gastric Cancer
- Hepatitis
Abstract
Citation: Ann Clin Case Rep. 2016;1(1):1104.DOI: 10.25107/2474-1655.1104
Pneumo-Enzymatic Vitreolysis for Resistant Vitreomacular Traction
Jorge G. Arroyo, Gina Yu, Rachel Tandias and Sushant Wagley
Department of Ophthalmology, Harvard Medical School, USA Hurley Medical Center, USA
*Correspondance to: Jorge G. Arroyo
PDF Full Text Case Report | Open Access
Abstract:
Aim: Case report describing a patient with resistant vitreomacular traction (VMT) treated with an intravitreal injection of a potentially safer, lower dose of ocriplasmin and with a residual intravitreal gas bubble from pneumatic vitreolysis.Case Report: An 88-year-old man with symptomatic vitreomacular traction (VMT) was observed for 4 weeks without spontaneous release. Pneumatic vitreolysis (PV, intravitreal injection of expansile gas with intermittent face-down positioning [FDP]) was performed. Four weeks later, a 30% bubble was still present in the vitreous, vision remained 20/70, and he had improved but persistent VMT. One-half of the recommended therapeutic dose of ocriplasmin was injected intravitreally and the patient continued FDP. At one-week follow-up, the patient had improved vision of 20/40, associated with complete VMT release. He had no adverse events.Discussion: Resistant VMT can lead to significant foveal distortion and subsequent vision loss. Pneumatic vitreolysis appears to successfully relieve VMT in about 80% of cases, but in the 20% of cases that do not respond, typically invasive, surgical intervention is required. This report shows the efficacy of combining the mechanical forces of PV with the enzymatic fibrinolytic activity available in a potentially safer, lower dose of ocriplasmin to treat resistant VMT cases, non-invasively.Summary: For resistant vitreomacular traction, combining the mechanical force of an intravitreal injection of an expansile gas with a half-dose of ocriplasmin could provide an efficacious treatment option, without the risk of the toxic safety profile often associated with ocriplasmin.
Keywords:
Ocriplasmin; Posterior vitreous detachment; Traction
Cite the Article:
Arroyo JG, Yu G, Tandias R, Wagley S. Pneumo-Enzymatic Vitreolysis for Resistant Vitreomacular Traction. Ann Clin Case Rep. 2016; 1: 1104.